Senti Biosciences (SNTI) Stock Is Up Over 100%: What's Happening?
Portfolio Pulse from Henry Khederian
Senti Biosciences Inc (NASDAQ:SNTI) shares surged by 102.6% to $0.56 after receiving an $8 million grant from the California Institute for Regenerative Medicines to support the development of SENTI-202, an investigational cell therapy for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The ongoing Phase 1 trial aims to provide initial efficacy data by the end of 2024 and durability data in 2025.
July 01, 2024 | 3:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Senti Biosciences Inc (NASDAQ:SNTI) shares surged by 102.6% to $0.56 after receiving an $8 million grant from the California Institute for Regenerative Medicines to support the development of SENTI-202, an investigational cell therapy for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML).
The $8 million grant is a significant financial boost for Senti Biosciences, supporting the development of SENTI-202. The market reacted positively, with the stock price surging over 100%. The ongoing Phase 1 trial and future data releases could further impact the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100